Team:ZJU-China/Background - 2020.igem.org
The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype | npj Breast Cancer
Frontiers | Non-conventional and Investigational PET Radiotracers for Breast Cancer: A Systematic Review
Breast cancer recurrence: factors impacting occurrence and survival | SpringerLink
PinPointcases - Adjuvant systemic treatment of luminal A/B early breast cancer
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer | npj Breast Cancer
Targeted therapies forge ahead in multiple breast cancer subtypes | MDedge Hematology and Oncology
The Prognosis Comparison of Different Molecular Subtypes of Breast Tumors After Radiotherapy and the Intrinsic reasons for Their Distinct Radiosensitivity - Oncology Nurse Advisor
Namarak Hospital
pCR After Neoadjuvant Chemotherapy in Luminal B Breast Cancer | Download Table
Targeted therapies forge ahead in multiple breast cancer subtypes | MDedge Hematology and Oncology
Study Suggests Luminal A Breast Cancer Patients May Not Need Chemotherapy - The ASCO Post
Envision Communications on Twitter: "Doctors use genetic information about breast cancer cells to categorize breast cancers and help guide decisions about which treatments are best. Did you know Luminal B breast cancers
Ki‑67 index value and progesterone receptor status can predict prognosis and suitable treatment in node‑negative breast cancer patients with estrogen receptor‑positive and HER2‑negative tumors
Efficacy of chemotherapy for lymph node-positive luminal A subtype breast cancer patients: an updated meta-analysis | World Journal of Surgical Oncology | Full Text
Molecular subtypes of breast cancer - What breast imaging radiologists need to know
![PDF] Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/5582615f848e686710455b6e112e876e1ab5fb5a/2-Table1-1.png "PDF] Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar")
PDF] Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. | Semantic Scholar
Biomedicines | Free Full-Text | Cooperation between Angiogenesis, Vasculogenesis, Chemotaxis, and Coagulation in Breast Cancer Metastases Development: Pathophysiological Point of View
pCR After Neoadjuvant Chemotherapy in Luminal B Breast Cancer | Download Table
that 64.4% and 67.2% of patients with Luminal A and Luminal B breast... | Download Scientific Diagram
Cancers | Free Full-Text | Valproic Acid and Breast Cancer: State of the Art in 2021
Breast cancer - The Lancet
